---
title: TeleRehabilitation in Hypertension
nct_id: NCT02705911
overall_status: COMPLETED
phase: NA
sponsor: KU Leuven
study_type: INTERVENTIONAL
primary_condition: Hypertension
countries: Belgium
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02705911.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02705911"
ct_last_update_post_date: 2022-03-08
last_seen_at: "2026-05-12T06:33:57.684Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# TeleRehabilitation in Hypertension

**Official Title:** Isometric Handgrip Exercise: a New Non-pharmacological Tool in the Management of High Blood Pressure?

**NCT ID:** [NCT02705911](https://clinicaltrials.gov/study/NCT02705911)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** KU Leuven
- **Collaborators:** Research Foundation Flanders
- **Conditions:** Hypertension, Pre-hypertension, Healthy
- **Start Date:** 2015-04
- **Completion Date:** 2016-07
- **CT.gov Last Update:** 2022-03-08

## Brief Summary

The purpose of this RCT which will be performed in 60 healthy adults is I. To assess the training effects of 8 weeks of isometric handgrip exercise on BP; and to test whether it yields at least similar effects on BP compared to current exercise recommendations.

II. To assess whether isometric handgrip training yields larger BP reductions beyond the supervised training period at 6 months of follow-up.

III. To determine whether changes in BP following acute exercise and chronic training can be explained by changes in important physiological mechanisms known to mediate or to be associated with BP?

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* not physically active (\< 3 hours of moderate to high levels of PA/week) low cardiovascular risk according to current guidelines (Mancia et al J Hypertens 2013) will be recruited through advertisements. The latter is defined as:
* \>115 mmHg \< systolic BP \< 139 mmHg and/or 75 mmHg\< diastolic BP\<90mmHg in the presence of 0 to a maximum of three other cardiovascular risk factors, excluding diabetes Or
* 139 mmHg \< systolic BP \< 160 mmHg and/or 90 mmHg\<DBP\< 100 mmHg in the absence of other cardiovascular risk factors

Exclusion Criteria:

* current smoker
* pregnancy
* presence of other cardiovascular disease, pulmonary disease or metabolic disease
* inability to perform a standard exercise program due to mental/physical disability.
* use of antihypertensive drugs
```

## Arms

- **Isometric Handgrip training** (EXPERIMENTAL) — Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
- **Aerobic endurance training** (ACTIVE_COMPARATOR) — Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
- **Control** (NO_INTERVENTION) — Participants are asked to continue with their daily routine and not to perform extra exercise.

## Interventions

- **Isometric handgrip exercise** (OTHER) — Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
- **Aerobic endurance training** (OTHER) — To perform 150 minutes extra/week at moderate aerobic intensity

## Primary Outcomes

- **change in office blood pressure at 8 weeks of follow-up** _(time frame: 8 weeks - 6 months)_

## Secondary Outcomes

- **change in exercise tolerance (peakVO2 in ml/min/kg) at 8 weeks of follow-up** _(time frame: 8 weeks - 6 months)_

## Locations (1)

- KU Leuven, Leuven, Belgium

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ku leuven|leuven||belgium` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02705911.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02705911*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*
